Deepak Madhavan, M.D., associate professor of neurological sciences at the University of Nebraska Medical Center, will discuss cannabidiol and its potential clinical use in treating patients suffering from epilepsy at the next Omaha Science Café at 7 p.m., Oct. 18 at the Slowdown, 729 N. 14th St.
Cannabidiol is a cannabinoid that is extracted from the Cannabis sativa plant and is distinct from tetrahydrocannabidiol (THC), the cannabinoid that is responsible for the drug-related high from smoking marijuana. Dr. Madhavan, who also is director of the Nebraska Comprehensive Epilepsy Program and clinical director of the Magnetoencephalography Center at Nebraska Medicine, is currently involved in the oversight of a clinical study that is investigating the use of cannabidiol in patients with drug resistant epilepsy.
Dr. Madhavan, completed his epilepsy fellowship at New York University, focusing on epilepsy surgery and magnetoencephalography. While at NYU, Dr. Madhavan was awarded a research and training fellowship for clinicians from the Epilepsy Foundation of America. In 2009, he founded Midwest Regional Epilepsy Associates, an epilepsy-focused private practice prior to joining UNMC.
Science Cafés involve a face-to-face conversation with a scientist about current science topics. They are open to everyone (21 and older) and take place in casual settings like pubs and coffeehouses. Each meeting is organized around an interesting topic of conversation. A scientist gives a brief presentation followed by a Q-and-A period.
Pizza will be provided for the first 50 people. For more information about Science Cafes, go to www.unmc.edu/sciencecafe. Podcasts of previous Science Cafes also are available on the website or available for download on iTunes here.
We are Nebraska Medicine and UNMC. Our mission is to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.